Monday, March 3rd, 2008
Clinical Data, Inc. (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced that its PGxHealth™ division has achieved significant growth in positive reimbursement policies for its FAMILION® genetic test for Long QT Syndrome (LQTS).
Since January 1, 2008, additional ...
Posted in Genetics | No Comments »
Monday, March 3rd, 2008
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced the completion of patient enrollment in its Phase 2a clinical trial for MB07803, a product candidate being studied as a treatment for patients with type 2 diabetes. With this trial fully enrolled and the final patients undergoing dosing, the Company expects to be able to ...
Posted in Diabetes | No Comments »
Monday, February 25th, 2008
Endometriosis is a condition of unknown etiology in which endometrial tissue occurs at extra-uterine sites, including ovaries, fallopian tubes, and gastrointestinal tract. It usually occurs between 30 and 40 years of age. Four to 17% of menstruating women develop endometriosis. When the disease involves the small bowel, it usually has ...
Posted in GastroIntestinal | No Comments »
Monday, February 25th, 2008
Sirtris Pharmaceuticals (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced that it will collaborate with the National Cancer Institute to test the anti-cancer impact of Sirtris' SIRT1 enzyme activators in numerous models of cancer.
"By providing the resources for this ...
Posted in Cancer / Oncology | No Comments »
Saturday, February 23rd, 2008
Arbios Systems, Inc. (OTC Bulletin Board: ABOS) announced that the Company has received conditional approval from the U.S. Food and Drug Administration ("FDA") of an Investigational Device Exemption ("IDE") to begin the pivotal clinical trial for SEPET(TM), Arbios' extracorporeal (outside the body) artificial liver assist device for blood purification of ...
Posted in Liver Disease / Hepatitis | No Comments »
Saturday, February 23rd, 2008
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced the acceptance of an abstract describing the results of a study using Xibrom(TM) (bromfenac ophthalmic solution) 0.09% therapy in combination with Lucentis(R) (ranibizumab injection) in patients with age-related macular degeneration (AMD). According to the abstract, patients who received Xibrom required 1.6 +/- 0.69 injections ...
Posted in Eye Health / Optometry | No Comments »
Saturday, February 23rd, 2008
ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products, announced initial clinical results of stand-alone ablation procedures and an overall expansion into the stand-alone market, using the ATS CryoMaze(TM) product line. This line of surgical products, indicated for the treatment of cardiac arrhythmias, is designed to ...
Posted in Cervical Cancer | No Comments »
Friday, February 22nd, 2008
Growth hormone boosts immune cell numbers
Individuals who are infected with HIV-1 are often highly susceptible to life-threatening infections because they are depleted of a subset of immune cells known as CD4+ T cells. A new study of individuals infected with HIV-1 by Laura Napolitano and colleagues at the Institute of ...
Posted in Biology / Biochemistry | No Comments »
Friday, February 22nd, 2008
The experimental microbicide Carraguard, a seaweed-based gel that blocked HIV infection of cells in lab tests is safe but does not provide women with protection against HIV infection, according to results from clinical trials conducted in three locations in South Africa, the Seattle Post-Intelligencer reports (Paulson, Seattle Post-Intelligencer, 2/18). According ...
Posted in HIV / AIDS | No Comments »
